30 October 2020 - Today the EMA has implemented two further extra transparency measures for COVID-19 medicines, by publishing both the clinical data in support of the authorisation of Veklury (remdesivir) and information on the COVID-19 treatments and vaccines that have received scientific advice or informal guidance from EMA’s pandemic Task Force (COVID-ETF).

These are the latest measures in EMA’s drive to maximise the transparency of its regulatory activities on treatments and vaccines for COVID-19.

Read EMA press release